High-Dose REirradiation for In-Field Recurrent Lung Cancer in the THOrax (RETHO): Outcomes of a Phase 2 Prospective Clinical Trial
This trial showed that high-dose thoracic reirradiation for recurrent lung cancer is effective and achieved a good OS higher than our null hypothesis. It resulted in good LC and DFS with low toxicity.
Authors
- M. Duijm (ORCID: https://orcid.org/0000-0001-6619-079X)
- Steven Petit (ORCID: https://orcid.org/0000-0001-9787-8239)
- Erik D. van Werkhoven (ORCID: https://orcid.org/0000-0001-7469-7427)
- J. Nuyttens
- W. Schillemans (ORCID: https://orcid.org/0000-0002-9485-5338)
- Eugenio Cammareri
- Ria Cornelissen
- J. Belderbos
- P.V. Granton
- J.L. Knegjens
Institutions
- The Netherlands Cancer Institute (NL)
- Erasmus MC Cancer Institute (NL)
Publication Details
- Journal
- International Journal of Radiation Oncology*Biology*Physics
- Published
- 2025-12-20
- DOI
- https://doi.org/10.1016/j.ijrobp.2025.12.024
- Primary Topic
- Lung Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00